RxDoctor Payments Data

Sharnette Washington

Family · Phoenix, AZNPI 1427522556

Payments from drug & device makers

$900in general payments, 2019–2025

Across 24 payments — averaging $37.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$380
  • AbbVie$167
  • Lilly USA, LLC$129
  • Organon$112
  • Novo Nordisk$51
  • Exact Sciences$43
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$88398%
  • Education$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott8$380
AbbVie7$167
Lilly USA, LLC2$129
Organon2$112
Novo Nordisk2$51
Exact Sciences2$43
Biotronik Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$900 in reported general payments places this provider in the 65th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$12,188
Medicare patients
81
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin16$24,510
OzempicSemaglutide13$15,870
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,013
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,705
Memantine Hcl ErMemantine Hcl13$1,107
Albuterol Sulfate HfaAlbuterol Sulfate29$854
Gabapentin40$850
Hydroxyzine Hcl25$806
Atorvastatin Calcium79$779
Levothyroxine Sodium71$709
Losartan Potassium57$644
Amlodipine Besylate74$502
Metoprolol Succinate42$499
Azelastine Hcl12$462
Omeprazole25$419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$51$15,87013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,119 family providers in Arizona.

Other family in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →